Navigation Links
Medical food reduces medical costs and use of anti-convulsant medication
Date:10/27/2009

ParisOct. 27, 2009Diabetic patients diagnosed with peripheral neuropathy had lower medical costs and reduced use of anticonvulsant medications when treated with a folate-enriched prescription medical food, according to data presented today at the International Society for Pharmacoeconomics and Outcomes Research 12th Annual European Congress.

The results of the HealthCore, Inc. study, funded by Pamlab, L.L.C., which manufactures the medical food Metanx, showed that patients' health plan costs to treat diabetes-related peripheral neuropathy were reduced by about $400 a year.

"In this study, health care savings were driven by lower costs related to hospitalization and outpatient services," said Ron Wade, lead researcher and research operations director for HealthCore, the outcomes research subsidiary for WellPoint, Inc. "Overall, this was more than a 30 percent reduction in costs for medical care related to diabetic peripheral neuropathy."

The study, "Administrative Claims Analysis of an L-Methylfolate Combination Product in Patients with Diabetic Peripheral Neuropathy," was co-authored by Wade and Qian Cai of HealthCore and Dr. Tina Thethi, assistant professor of endocrinology, Tulane School of Medicine. The abstract for this study was published in the Sept. 15 online edition of Value in Health.

Diabetic peripheral neuropathy is a disorder of the peripheral nerves usually affecting the hands and feet, causing weakness, numbness, tingling and pain. Anticonvulsant medication is commonly used to control these symptoms.

The HealthCore study found that the group of patients prescribed Metanx tablets reduced their use of anticonvulsants by 31 percent one year after treatment, compared with the control group that reduced their use by 10 percent.

Metanx contains L-methylfolate, pyridoxyl-5-phosphate, and methylcobalmin and has been shown in pilot studies to increase epidermal nerve fiber density in humans, restore sensation and reduce neuropathic pain by increasing nitric oxide levels, which improves endothelial function and increases blood flow to the nerves in the hands and feet.

"From clinical trials, we are seeing what Metanx can do clinically, but it is also reassuring to know that in this time of soaring health care costs that Metanx may help reduce costs related to patients with diabetic peripheral neuropathy," said Chet Busby, head of Pamlab's scientific affairs.


'/>"/>

Contact: Lori McLaughlin
lori.mclaughlin2@wellpoint.com
317-407-7403
HealthCore
Source:Eurekalert

Related biology news :

1. American College of Medical Genetics responds to new FDA labeling decision for warfarin
2. M2SYS Partners With Gnosis Medical Services to Provide Accurate Patient Identification in Developing Countries Through Innovative Biometrics Solution
3. Boston University biomedical engineers find chink in bacterias armor
4. $22 million gift from Alfred Taubman launches new biomedical research institute
5. USC biomedical team to participate in $6 million low vision project
6. 3 Columbia University Medical Center faculty elected to Institute of Medicine
7. Phase 2 of Singapores Biomedical Sciences Initiative gains momentum for clinical research
8. UMass Medical School researchers receive $8.5M grant award to fight AIDS
9. Natural product discovery by Cleveland medical researchers blocks tissue destruction
10. Triage study challenges notions of emergency medical response to disaster
11. Titanium Group Signs Letter of Intent to Acquire Multimilion Dollar Medical Software Company and Its Existing Sales Network
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/9/2017)... MOUNTAIN VIEW, Calif. , March 9, 2017 ... and 23andMe , the leading personal genetics company, ... Zipongo can now provide customers with personalized nutrition plans ... and biometrics, but also genetic markers impacting how their ... Zipongo,s personalized food decision support platform uses biometrics such ...
(Date:3/7/2017)...   HireVue , the leading provider of video ... best talent, faster, today announced the additions of ... Diana Kucer as Chief Marketing Officer (CMO). ... poised to drive continued growth in the company,s new ... record bookings in 2017. "Companies worldwide turn ...
(Date:3/2/2017)... Summary This report provides all the ... interests and activities since 2010. ... Read the full report: http://www.reportlinker.com/p03605615-summary/view-report.html ... report provides an in-depth insight into the partnering activity of ... On demand company reports are prepared upon purchase to ensure ...
Breaking Biology News(10 mins):
(Date:3/24/2017)... 24, 2017 Agenus Inc. (NASDAQ: AGEN), an ... and cancer vaccines, today announced participation at the following ... William Blair and Maidstone Life Sciences conference "Cancer Immunotherapy ... New York, NY . Agenus will ... at 9:40 am: Robert B. Stein , M.D., ...
(Date:3/23/2017)... Mar 23, 2017 Research and Markets ... Markets" report to their offering. ... The Global Market for ... in 2016 at a CAGR of 8.9%, ... non-energetic bioproducts into seven major product segments: bio-derived chemicals, biofuels, ...
(Date:3/23/2017)...  GlobeImmune, Inc. today announced it has entered into ... shares of its common stock to NantCell, Inc., a ... the sale of its common stock, NantCell has agreed ... GlobeImmune 200,000 shares, an estimated $2.0 million in value, ... pleased to enter into this strategic agreement with NantCell," ...
(Date:3/23/2017)... March 23, 2017 Kineta, Inc., a ... novel therapies in immuno-oncology, today announced the discovery ... molecule compounds that activate interferon response factor 3 ... demonstrate immune-mediated tumor regression in a murine colon ... who demonstrated complete tumor regression to initial drug ...
Breaking Biology Technology: